Amgen (AMGN): FY25 Q4 earnings call, Feb 3, 2026
No Kalshi or Polymarket word markets were listed for Amgen’s Feb 3, 2026 earnings call (FY25 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
2 matches for “VESALIUS-CV”; 2 quoted, at least 25 words apart.
…cardiovascular health from Repatha. In November, full results from the Phase III Vesalius CV trial were presented at the American Heart Association Scientific Sessions and…
…therapy. Namely statins, with a median follow-up of approximately 4.5 years. In Vesalius CV, we're demonstrated a 25% relative risk reduction in the composite of…
Agents: this page as TSV at /api/v1/appearances/amgen:2026-02-03:earnings_call · words: /api/v1/brief?appearance=amgen:2026-02-03:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP